<DOC>
	<DOCNO>NCT01675154</DOCNO>
	<brief_summary>Funding Source - FDA OOPD This study do find whether investigational ( approved FDA ) drug call SLx-4090 Orlistat ( FDA approve medication weight loss ) give alone combination treat high blood fat ( elevate triglyceride ) level find condition Type 1 Hyperlipoproteinemia ( T1HLP ) well safely low fat diet alone , current standard medical care . It also clear whether Orlistat , FDA approve weight loss , effective lower blood fat level patient Type 1 hyperlipoproteinemia ( T1HLP ) . The researcher interested learn whether one drug give alone combination effective safe treat T1HLP .</brief_summary>
	<brief_title>Phase 2 Study Orlistat SLx-4090 Treatment Type 1 Hyperlipoproteinemia</brief_title>
	<detailed_description>Type I hyperlipoproteinemia rare , autosomal recessive metabolic disorder characterize extreme hypertriglyceridemia due deficiency lipoprotein lipase related protein . Treatment patient challenge triglyceride-lowering medication ineffective . A low fat diet helpful , however , despite good dietary compliance , patient continue severe hypertriglyceridemia recurrent pancreatitis life threaten . Therefore , wish investigate whether induce dietary fat malabsorption inhibit chylomicron formation cause lower serum triglyceride ( TG ) beyond effect limit dietary fat intake . We study efficacy safety inhibitor intestinal lipase ( Orlistat ) intestinal-specific inhibitor microsomal triglyceride transport protein ( MTP ) involve assembly secretion chylomicron ( SLx-4090 ) , alone combination , reduce serum triglyceride level patient Type I hyperlipoproteinemia . We plan enroll 20 patient Type I hyperlipoproteinemia randomize , double-blind , placebo-controlled , cross-over trial . After baseline evaluation , subject randomly assign placebo/placebo , Orlistat/placebo , SLx-4090/placebo Orlistat/SLx-4090 duration four week follow one week wash period . During last week study period , fast blood sample draw three consecutive day serum lipids chemistry panel . The primary endpoint serum triglyceride ; secondary endpoint variable fast postprandial serum chylomicron-TG level , postprandial serum TG level meal tolerance test retinyl palmitate level meal tolerance test . Repeated measure analysis variance use statistical comparison . Our result may help design novel therapeutic approach patient Type 1 hyperlipoproteinemia .</detailed_description>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>Type I hyperlipoproteinemia . Fasting serum triglyceride level great 1000 mg/dL . Age &gt; 12 year Secondary hypertriglyceridemias due diabetes , renal disease , hypothyroidism , alcoholism drug therapy estrogens estrogen analogue , steroid , HIVprotease inhibitor , retinoic acid derivative interferon . Pregnant lactate woman Significant liver disease ( elevated transaminase &gt; 2 time upper limit normal ) Alcohol abuse ( &gt; 7 drink 84 g per week woman &gt; 14 drink men 168 g per week men ) Drug use ( cocaine , marijuana , LSD , etc . ) Major surgery past three month Congestive heart failure Serum creatinine great 2.5 mg/dL Cancer within past five year Gastrointestinal surgery past Current therapy anticoagulant , digoxin antiarrhythmic Chronic malabsorption syndrome Cholestasis Acute illnesses acute pancreatitis last 8 week</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>hypertriglyceridemia</keyword>
</DOC>